AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17595241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1700 mg/d metformin treatment for 6 months
Number of subjects: 80
Study 17595241 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) administered using a traditional incremental-dose protocol for 6 months
Number of subjects: 80
Study 15208137 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy
Number of subjects: 58
Study 15208137 — intervention group
Group type: COMPARATOR
Intervention: Gallbladder aspiration
Number of subjects: 58
Study 11252300 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide
Number of subjects: 38
Study 11252300 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 38
Study 9764962 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral dose of tacrine
Number of subjects: 19
Study 7942079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive treatment
Number of subjects: 5
Study 3354631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanding a cutting board (product-oriented activity)
Number of subjects: 15
Study 3354631 — intervention group
Group type: COMPARATOR
Intervention: Sanding a piece of wood (non-product-oriented activity)
Number of subjects: 15
Study 31593756 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HF) - 64.6 Gy in 19 fractions
Number of subjects: 804
Study 31593756 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiation therapy (CF) - 78.0 Gy in 39 fractions
Number of subjects: 804
Study 31593756 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in HF
Number of subjects: 804
Study 29393690 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 µg vaginal misoprostol 6 hours before IUD insertion
Number of subjects: 120
Study 29393690 — intervention group
Group type: COMPARATOR
Intervention: Placebo 6 hours before IUD insertion
Number of subjects: 120
Study 27017234 — intervention group
Group type: EXPERIMENTAL
Intervention: Women referred to imaging tests (adjusted odds ratio: 1.21; 95% confidence interval: 1.01 to 1.44)
Number of subjects: 10003
Study 27017234 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 10003
Study 27017234 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 10003
Study 24622517 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue hormone therapy (HT+)
Number of subjects: 45
Study 24622517 — intervention group
Group type: COMPARATOR
Intervention: Discontinue hormone therapy (HT-)
Number of subjects: 45
Study 24622517 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) based HT
Number of subjects: 45
Study 24622517 — intervention group
Group type: COMPARATOR
Intervention: Concurrent progestins with either 17βE or CEE
Number of subjects: 45
Study 23527013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 400 IUs daily for 2 months
Number of subjects: 8
Study 23527013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 2000 IUs daily for 2 months
Number of subjects: 8
Study 23527013 — intervention group
Group type: COMPARATOR
Intervention: Baseline vitamin D deficiency (25(OH)D<20 ng/ml)
Number of subjects: 8
Study 23527013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (both dosages)
Number of subjects: 8
Study 20653150 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 76
Study 20653150 — intervention group
Group type: COMPARATOR
Intervention: BHI 30
Number of subjects: 76
Study 17440528 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-rich diet (2 g/day sitosterol)
Number of subjects: 30
Study 17440528 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-rich diet (1 g/day sitosterol)
Number of subjects: 30
Study 17440528 — intervention group
Group type: COMPARATOR
Intervention: Low cholesterol diet
Number of subjects: 30
Study 15916620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15916620 — intervention group
Group type: COMPARATOR
Intervention: Fulfillment of the Rome criteria for study entry
Number of subjects: 45
Study 15916620 — intervention group
Group type: COMPARATOR
Intervention: Increased number of office visits
Number of subjects: 45
Study 14636092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 repetitions of 3-second maximal voluntary isometric contractions (MVC)
Number of subjects: 14
Study 14636092 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of prior loading)
Number of subjects: 14
Study 10972368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg (long-acting gastrointestinal-transport-system formulation)
Number of subjects: 6321
Study 10972368 — intervention group
Group type: COMPARATOR
Intervention: Co-amilozide (hydrochlorothiazide 25 mg plus amiloride 2.5 mg)
Number of subjects: 6321
Study 10972368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6321
Study 10972368 — intervention group
Group type: COMPARATOR
Intervention: Co-amilozide
Number of subjects: 6321
Study 10972368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Co-amilozide
Number of subjects: 6321
Study 8797136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate (1.2, 1.8, and 2.4 mg/kg i.v.)
Number of subjects: 30
Study 8797136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (32 mg i.v.)
Number of subjects: 30
Study 8797136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8459374 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of droperidol, hyoscine, and metoclopramide in subtherapeutic doses
Number of subjects: 0
Study 8459374 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (1.25 mg) alone
Number of subjects: 0
Study 3080868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (50 g soya oil emulsified with egg lecithin)
Number of subjects: 6
Study 3080868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipofundin (50 g soya oil emulsified with soya lecithin)
Number of subjects: 6
Study 3080868 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study 31504427 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 or 25 mg
Number of subjects: 7020
Study 31504427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 31504427 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 29468708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-included multidisciplinary team care (MTC) group
Number of subjects: 79
Study 29468708 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 79
Study 26988798 — intervention group
Group type: EXPERIMENTAL
Intervention: Arjuna extract 750 mg twice daily
Number of subjects: 100
Study 26988798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26491093 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated complete right bundle branch block (n=98)
Number of subjects: 98
Study 26491093 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults (control group, n=92)
Number of subjects: 98
Study 23444397 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT (extended release niacin 2 g plus laropiprant 40 mg daily)
Number of subjects: 25673
Study 23444397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25673
Study 21253392 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily
Number of subjects: 148
Study 21253392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + sodium fluoride (25 mg bid)
Number of subjects: 148
Study 21253392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + ibandronate (1 mg iv/3‐monthly)
Number of subjects: 148
Study 18291177 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation self-management (group 2, n = 470)
Number of subjects: 765
Study 18291177 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation management (group 1, n = 295)
Number of subjects: 765
Study 16783144 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Betadine
Number of subjects: 35
Study 16783144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (preservative-free artificial tears)
Number of subjects: 35
Study 12678277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with maculopathy
Number of subjects: 41
Study 12678277 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-ARMD patients
Number of subjects: 41
Study 12678277 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 41
Study 10886042 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alosetron
Number of subjects: 25
Study 10886042 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg alosetron
Number of subjects: 25
Study 10886042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8922317 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary directional coronary atherectomy (DCA)
Number of subjects: 21
Study 8922317 — intervention group
Group type: COMPARATOR
Intervention: Primary balloon angioplasty
Number of subjects: 21
Study 1397674 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/kg captopril
Number of subjects: 28
Study 1397674 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day enalapril
Number of subjects: 28
Study 1397674 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day delapril hydrochloride
Number of subjects: 28
Study 3893601 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 69
Study 3893601 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 69
Study 3893601 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 69
Study 30714866 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary bladder lavage (flush group; n = 69)
Number of subjects: 137
Study 30714866 — intervention group
Group type: COMPARATOR
Intervention: No urinary bladder lavage (no-flush group; n = 68)
Number of subjects: 137
Study 29635142 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for panic disorder (PD)
Number of subjects: 251
Study 29635142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 251
Study 26714287 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype-based tacrolimus dosing
Number of subjects: 240
Study 26714287 — intervention group
Group type: COMPARATOR
Intervention: Standard, body-weight-based tacrolimus dosing
Number of subjects: 240
Study 25302017 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg buccal acetaminophen (bAPAP)
Number of subjects: 16
Study 25302017 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg buccal acetaminophen (bAPAP)
Number of subjects: 16
Study 25302017 — intervention group
Group type: COMPARATOR
Intervention: 1 g intravenous acetaminophen (ivAPAP)
Number of subjects: 16
Study 25302017 — intervention group
Group type: COMPARATOR
Intervention: 125 mg sublingual acetaminophen (sAPAP)
Number of subjects: 16
Study 22572418 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once weekly)
Number of subjects: 48
Study 22572418 — intervention group
Group type: COMPARATOR
Intervention: Oral penicillin (phenoxy methyl penicillin 250 mg twice daily)
Number of subjects: 48
Study 20840200 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief treatment (two-session)
Number of subjects: 450
Study 20840200 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment (nine-session)
Number of subjects: 450
Study 20840200 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 450
Study 18047921 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/day
Number of subjects: 40
Study 18047921 — intervention group
Group type: COMPARATOR
Intervention: valsartan 80 mg/day
Number of subjects: 40
Study 16231111 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (Chlorhexamed) for 15 minutes (3 x 5 min) every 12 weeks
Number of subjects: 68
Study 16231111 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (EC40) every 12 weeks
Number of subjects: 68
Study 16231111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Fluoridin) applied to all teeth 4 and 8 weeks after CHX treatments
Number of subjects: 68
Study 11806641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl (smear layer intact)
Number of subjects: 150
Study 11806641 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA and 5.25% NaOCl (smear layer removed)
Number of subjects: 150
Study 11806641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum method
Number of subjects: 150
Study 11806641 — intervention group
Group type: COMPARATOR
Intervention: Presence or absence of smear layer
Number of subjects: 150
Study 10527991 — intervention group
Group type: EXPERIMENTAL
Intervention: Single embryo transfer
Number of subjects: 110
Study 10527991 — intervention group
Group type: COMPARATOR
Intervention: Double embryo transfer
Number of subjects: 110
Study 8750365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril-chlorthalidone combination treatment (5 mg + 25 mg)
Number of subjects: 32
Study 8750365 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone monotherapy (25 mg daily)
Number of subjects: 32
Study 1476027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 20
Study 1476027 — intervention group
Group type: COMPARATOR
Intervention: KMn04 (diluted at 1:20,000)
Number of subjects: 20
Study 6476070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking activity
Number of subjects: 22
Study 6476070 — intervention group
Group type: COMPARATOR
Intervention: Craft activity
Number of subjects: 22
Study 6476070 — intervention group
Group type: COMPARATOR
Intervention: Sensory awareness activity
Number of subjects: 22
Study 31278021 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 0
Study 31278021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 0
Study 29693757 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive probiotics (Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12)
Number of subjects: 66
Study 29693757 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 66
Study 29693757 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive probiotics
Number of subjects: 66
Study 27275617 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary Anchorage Devices (TADs) for canine disimpaction before bracket placement
Number of subjects: 34
Study 27275617 — intervention group
Group type: COMPARATOR
Intervention: Cantilever spring soldered to a palatal bar for canine disimpaction after initiation of comprehensive orthodontics
Number of subjects: 34
Study 25317545 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.015 mg/kg
Number of subjects: 108
Study 25317545 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 108
Study 22525902 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 2304
Study 20353028 — intervention group
Group type: EXPERIMENTAL
Intervention: Liangxue Shengji Recipe (LSR)
Number of subjects: 100
Study 20353028 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western treatment
Number of subjects: 100
Study 17663737 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 3 mg
Number of subjects: 174
Study 17663737 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 10 mg
Number of subjects: 174
Study 17663737 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 30 mg
Number of subjects: 174
Study 17663737 — intervention group
Group type: EXPERIMENTAL
Intervention: YM150 60 mg
Number of subjects: 174
Study 17663737 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg daily)
Number of subjects: 174
Study 15591292 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 65% V(O2 peak)
Number of subjects: 12
Study 15591292 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 45% V(O2 peak)
Number of subjects: 12
Study 15591292 — intervention group
Group type: COMPARATOR
Intervention: Con (no-exercise)
Number of subjects: 12
Study 15591292 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise recovery after 45% exercise
Number of subjects: 12
Study 15591292 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise recovery after 65% exercise
Number of subjects: 12
Study 12393314 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (immediate release and extended release)
Number of subjects: 2045
Study 12393314 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 2045
Study 12393314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study 12393314 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine vs. SSRIs
Number of subjects: 2045
Study 12393314 — intervention group
Group type: EXPERIMENTAL
Intervention: Final subscale scores
Number of subjects: 2045
Study 9928755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg once daily
Number of subjects: 200
Study 9928755 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 2.5 mg once daily
Number of subjects: 200
Study 7755188 — intervention group
Group type: EXPERIMENTAL
Intervention: Artery-ligated group
Number of subjects: 66
Study 7755188 — intervention group
Group type: COMPARATOR
Intervention: Artery-preserved group
Number of subjects: 66
Study 7755188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 2373879 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 58
Study 2373879 — intervention group
Group type: COMPARATOR
Intervention: Bacterial pathogens alone
Number of subjects: 58
Study 6756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine 20 mg, 4 times a day
Number of subjects: 28
Study 6756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine 60 mg
Number of subjects: 28
Study 6756418 — intervention group
Group type: COMPARATOR
Intervention: Niludipine 60 mg in normotensives
Number of subjects: 28
Study 6756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine + Propranolol 10 mg, 4 times a day
Number of subjects: 28
Study 6756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Niludipine + Propranolol + Penfluzide 2.5 mg a day
Number of subjects: 28
Study 30570162 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus gastric feeding (B-GF)
Number of subjects: 25
Study 30570162 — intervention group
Group type: COMPARATOR
Intervention: Continuous gastric feeding (C-GF)
Number of subjects: 25
Study 29977846 — intervention group
Group type: EXPERIMENTAL
Intervention: W incision
Number of subjects: 93
Study 29977846 — intervention group
Group type: COMPARATOR
Intervention: Inverted-V incision
Number of subjects: 93
Study 26499175 — intervention group
Group type: EXPERIMENTAL
Intervention: LEO 43204 0·025%
Number of subjects: 40
Study 26499175 — intervention group
Group type: EXPERIMENTAL
Intervention: LEO 43204 0·05%
Number of subjects: 40
Study 26499175 — intervention group
Group type: EXPERIMENTAL
Intervention: LEO 43204 0·075%
Number of subjects: 40
Study 26499175 — intervention group
Group type: COMPARATOR
Intervention: ingenol mebutate 0·05%
Number of subjects: 40
Study 24907420 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective hepatic vascular exclusion (SHVE)
Number of subjects: 160
Study 24907420 — intervention group
Group type: COMPARATOR
Intervention: Pringle manoeuvre
Number of subjects: 160
Study 22662740 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 22662740 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19654139 — intervention group
Group type: COMPARATOR
Intervention: Bone-marrow-derived stem cells (BMSC) administered by intracoronary infusion
Number of subjects: 1091
Study 19654139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-marrow-derived stem cells (BMSC) delivered by intra-myocardial injection
Number of subjects: 1091
Study 19654139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-marrow-derived stem cells (BMSC) in chronic IHD patients with lower baseline LVEF
Number of subjects: 1091
Study 17617290 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Number of subjects: 53
Study 17617290 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Number of subjects: 53
Study 17617290 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic terazosin
Number of subjects: 53
Study 17617290 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded terazosin
Number of subjects: 53
Study 14694168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone plus oral prednisone
Number of subjects: 86
Study 14694168 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 86
Study 11576413 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate ointment
Number of subjects: 40
Study 11576413 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% fluticasone proprionate ointment
Number of subjects: 40
Study 11576413 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet wraps with either ointment after 2 weeks
Number of subjects: 40
Study 9506330 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 17944
Study 8034522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (half-life 8 hours)
Number of subjects: 429
Study 8034522 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (half-life 2 hours)
Number of subjects: 429
Study 8034522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone/Ornidazole (half-life 13 hours)
Number of subjects: 429
Study 8034522 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin/Metronidazole (half-life 8 hours)
Number of subjects: 429
Study 8034522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole
Number of subjects: 429